Pharmaceutical News

RSS

Researchers identify novel approach to decrease glioblastoma multiforme recurrence

Researchers from the University of Massachusetts Medical School have identified a novel approach of combining chemotherapy with a targeted therapy to decrease the recurrence of glioblastoma multiforme, the most common and aggressive brain tumor.

25 Aug 2010

SureGene collaborates with Medco Health Solutions to conduct REST study

SureGene, LLC and the Medco Research Institute, LLC, a wholly-owned subsidiary of Medco Health Solutions, Inc., today announced that they have entered into a novel investigative research collaboration to evaluate whether variation in genetic biomarkers previously identified by SureGene can help predict drug response for widely prescribed antipsychotic drugs in patients with serious mental illness.

25 Aug 2010

Prollenium enters supply and distribution partnership with Canderm for Ovita HV dermal filler

Prollenium and Canderm GP, an affiliate of sanofi-aventis Canada, have entered into a supply and distribution partnership for Ovita HV, a Hyaluronic Acid (HA) based dermal filler.

25 Aug 2010

Survey finds women interested in human papillomavirus vaccination

Cost but not convenience plays a significant role in attitudes about vaccination for common human papillomaviruses for women over the age of 26, according to the authors of a recent article in the journal Sexual Health.

25 Aug 2010

FDA grants Fast Track Designation to Celsion's ThermoDox for liver cancer treamtment

Celsion Corporation, a leading oncology drug development company, today announced that the U.S. Food and Drug Administration has designated the HEAT Study of its investigational drug, ThermoDox, in combination with radiofrequency ablation, as a Fast Track Development Program.

25 Aug 2010

Advanced Life Sciences seeks government funding for development of Restanza antibiotic

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced plans to seek additional government funding for development of its novel, once-daily antibiotic, Restanza.

25 Aug 2010

BioAlliance Pharma launches Oravig drug in the U.S. market

BioAlliance Pharma SA, a company dedicated to the supportive care and treatment of cancer patients, today announces the launch in the United States of Oravig® (known as Loramyc® in Europe) for the treatment of oropharyngeal candidiasis (OPC) in adults by its commercial partner, Strativa Pharmaceuticals, the proprietary products division of Par Pharmaceutical Companies, Inc..

25 Aug 2010

NICE draft guidance rejects cancer drug bevacizumab

The National Institute for Health and Clinical Excellence (NICE) has released draft guidance for cancer drug bevacizumab (Avastin).

25 Aug 2010

3SBio and Isotechnika enter strategic agreement for voclosporin in China

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products and Isotechnika Pharma Inc., a biopharmaceutical company focused on the discovery and development of immune modulating therapeutics, today announced the signing of a development and commercialization agreement for voclosporin.

24 Aug 2010

Aileron Therapeutics, Roche partner to develop, commercialise Stapled Peptide Therapeutics

Aileron Therapeutics and Roche announced today that they have entered into a collaboration to discover, develop and commercialise a new class of drugs called Stapled Peptide Therapeutics. As part of this agreement, Roche will work with Aileron to develop drug candidates against up to five undisclosed targets selected from Roche's key therapeutic areas, which include oncology, virology, inflammation, metabolism and CNS.

24 Aug 2010

Raptor Pharmaceutical updates on cysteamine bitartrate Phase 3 clinical trial in cystinosis patients

Raptor Pharmaceutical Corp.,provides updates on timelines related to its clinical programs including the pivotal Phase 3 clinical trial of its proprietary delayed-release oral formulation of cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis").

24 Aug 2010

Deutsches Ärzteblatt International presents new PRISCUS List

In the current issue of Deutsches Ärzteblatt International (Dtsch Arztebl Int 2010; 107[31-32]: 543-51), Stephanie Holt, a clinical pharmacologist, and coauthors present the PRISCUS List: a list of medications that carry an increased risk of side effects when given to elderly patients.

24 Aug 2010

Department of Health to hold vaccination drive for whooping cough

With some areas of the state seeing an increase in whooping cough, known medically as pertussis, the Department of Health urges all Pennsylvanians to ensure they are protected against the vaccine-preventable disease.The department will soon hold public vaccination clinics in York and Delaware counties, where cases of pertussis have been rising.

24 Aug 2010

OSDD program aims to develop new drug for tuberculosis

An unlikely effort is underway to lift the veil of nearly-total secrecy that has surrounded the process of developing new prescription drugs for the last century, scientists said today at the 240th National Meeting of the American Chemical Society (ACS). The upheaval in traditional practice would make key data available to college students, university professors, and others in an open, collective process.

24 Aug 2010

Medivir appoints Daewoong as South Korean distributor for Xerclear

Medivir AB today announced it has appointed Daewoong Pharmaceutical Co. Ltd. as its exclusive distributor for Xerclear™ in South Korea. Under the terms of the agreement, Daewoong will be responsible for obtaining the regulatory approvals, and for marketing, sales and distribution of Medivir's cold sore product in the territory. In consideration of the rights granted to Daewoong, Medivir will receive upfront and milestone payments and royalties on sales according to a profit sharing scheme.

24 Aug 2010

Removing corticosteroid regimen after surgery results in better graft survival rates

University of Cincinnati (UC) analysis of 10 years of data from local kidney transplant patients shows that patients removed from a corticosteroid regimen shortly after surgery have better graft survival rates, better survival rates and fewer cardiovascular events than patients kept on the traditional regimen of long-term steroids.

24 Aug 2010

Baxter announces definitive agreement with Kamada for GLASSIA alpha1-proteinase inhibitor

Baxter International Inc. today announced a definitive agreement with Kamada Ltd. for exclusive commercial rights to GLASSIA™ [Alpha 1-Proteinase Inhibitor (Human)], the first and only liquid alpha1-proteinase inhibitor, in the United States, Australia, New Zealand and Canada.

From Baxter International Inc. 24 Aug 2010

AP reports on efforts to monitor authenticity of antimalarials, other drugs in Africa

The Associated Press reports on a recent effort to use text messages to track the authenticity of antimalarials in Africa, where "more than 30 percent of malaria medicines are estimated to be fake."

24 Aug 2010

Pfizer's Prevenar 13-valent pneumococcal conjugate vaccine receives WHO prequalification

The World Health Organization (WHO) has granted prequalification to Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed])for active immunization of infants and children from 6 weeks through five years of age against invasive disease, pneumonia and otitis media caused by the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) contained in the vaccine.

24 Aug 2010

Publix Super Markets to introduce flu immunization program

"Flu clinics are an extension of the services our pharmacies provide to our customers as a convenient and affordable way to receive their vaccinations," said Maria Brous, Publix director of media and community relations. "At Publix, our pharmacies are dedicated to building relationships with our customers and their families for total health and wellness all year long."

23 Aug 2010

Pharmaceutical News

Researchers identify novel approach to decrease glioblastoma multiforme recurrence

SureGene collaborates with Medco Health Solutions to conduct REST study

Prollenium enters supply and distribution partnership with Canderm for Ovita HV dermal filler

Survey finds women interested in human papillomavirus vaccination

FDA grants Fast Track Designation to Celsion's ThermoDox for liver cancer treamtment

Advanced Life Sciences seeks government funding for development of Restanza antibiotic

BioAlliance Pharma launches Oravig drug in the U.S. market

NICE draft guidance rejects cancer drug bevacizumab

3SBio and Isotechnika enter strategic agreement for voclosporin in China

Aileron Therapeutics, Roche partner to develop, commercialise Stapled Peptide Therapeutics

Raptor Pharmaceutical updates on cysteamine bitartrate Phase 3 clinical trial in cystinosis patients

Deutsches Ärzteblatt International presents new PRISCUS List

Department of Health to hold vaccination drive for whooping cough

OSDD program aims to develop new drug for tuberculosis

Medivir appoints Daewoong as South Korean distributor for Xerclear

Removing corticosteroid regimen after surgery results in better graft survival rates

Baxter announces definitive agreement with Kamada for GLASSIA alpha1-proteinase inhibitor

AP reports on efforts to monitor authenticity of antimalarials, other drugs in Africa

Pfizer's Prevenar 13-valent pneumococcal conjugate vaccine receives WHO prequalification

Publix Super Markets to introduce flu immunization program

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News